Duodenal mucosal resurfacing shown to discontinue insulin treatment in majority of type 2 diabetes patients and aid weight loss

Duodenal mucosal resurfacing (DMR) is an endoscopic intervention in which the duodenal mucosa is ablated by hydrothermal energy. DMR improves glycemic control in patients with type 2 diabetes (T2D), most likely by altered duodenal signaling leading to insulin sensitization. We studied whether we could discontinue insulin use in T2D patients by combining DMR with glucagon-like peptide-1 receptor agonist (GLP-1RA) and lifestyle counseling. https://pubmed.ncbi.nlm.nih.gov/33359437/

Allergy-related diseases and IBS

Asthma and food hypersensitivity at age 12 is associated with an increased risk of having irritable bowel syndrome at 16, a new study presented at UEG Week Virtual 2020 has found. The research, conducted at the University of Gothenburg and the Karolinska Institute in Stockholm, Sweden, analysed the health of 2,770 children from birth to the age of 16. Those with IBS at 16 were almost twice as likely to have had asthma at the age of 12 (11.2% vs 6.7%). Almost half of children with IBS at 16 (40.7%) reported food hypersensitivity at 12 years (compared to 29.2% of children without IBS at 16).

Transmural healing in IBD

Prof Ghosh illustrated the importance of transmural healing in inflammatory bowel disease management.

A Next-Generation, Dual-Action Anti-Integrin Therapy for IBD

Prof. Rubin speaks about the newer anti‑integrin therapies, like etrolizumab.

How to sequence advanced therapies in IBD

Prof. Schreiber speaks about evidence from clinical trials and real-world experience.

EUS guided liver biopsy

Endoscopic measurement of portal vein pressure

Hepatic Safety Overview of Obeticholic Acid for the Treatment of Patients with Primary Biliary Cholangitis

Control Study: Effects of Obeticholic Acid and Atorvastatin Treatment on Lipoprotein Metabolism in Patients with Nonalcoholic Steatohepatitis

Real Life Rates of Sustained Virological Response Of Sofosbuvir/Velpatasvir Treatment in HCV Genotype GT 1-2-3-4-6

Acute Autoimmune Hepatitis: Steroids and Timing of Liver Transplant

Non-Invasive Assessment of Fibrosis: Are We There Yet?

Risk of Hepatitis C transmission from antibody positive-nucleic acid negative liver organs to antibody negative recipients

Impact of Sustained Virologic Response with Direct-Acting Antiviral Treatment on Mortality and Hepatocellular Carcinoma

Acute liver injury due to immunotherapy for metastatic cancer: a new challenge

Improved Short-Term Survival in HCV Patients following Liver Transplantation in the Era of Direct Acting Antiviral Agents